Loss-of-function mutation in Pcsk1 increases serum APOA1 level and LCAT activity in mice

Aleksandra Aljakna Khan1, Nakyung Kim2, Ron Korstanje* and Seungbum Choi1,2*

Abstract

Background: The convertase subtilisin/kexin family 1 gene (PCSK1) has been associated in various human genetics studies with a wide spectrum of metabolic phenotypes, including early-onset obesity, hyperphagia, diabetes insipidus, and others. Despite the evident influence of PCSK1 on obesity and the known functions of other PCSKs in lipid metabolism, the role of PCSK1 specifically in lipid and cholesterol metabolism remains unclear. This study evaluated the effect of loss of PCSK1 function on high-density lipoprotein (HDL) metabolism in mice.

Results: HDL cholesterol, apolipoprotein A1 (APOA1) levels in serum and liver, and the activities of two enzymes (lecithin-cholesterol acyltransferase, LCAT and phospholipid transfer protein, PLTP) were evaluated in 8-week-old mice with a non-synonymous single nucleotide mutation leading to an amino acid substitution in PCSK1, which results in a loss of protein's function. Mutant mice had similar serum HDL cholesterol concentration but increased levels of serum total and mature APOA1, and LCAT activity in comparison to controls.

Conclusions: This study presents the first evaluation of the role of PCSK1 in HDL metabolism using a loss-of-function mutant mouse model. Further investigations will be needed to determine the underlying molecular mechanism.

Keywords: Prohormone convertase, Lipoprotein, Cholesterol, High-density lipoprotein, Quantitative trait locus

Background

The convertase subtilisin/kexin family (PCSKs) are endopeptidases, which cleave immature proproteins (precursors) to generate mature functional proteins [1]. Their targets comprise various prohormones and proneuropeptides. Both rare and common mutations in PCSK1 (also known as prohormone convertase 1/3 or PC1/3) have been associated with obesity [2], and in various human genetic studies with a wide spectrum of metabolic phenotypes, including hyperphagia, intestinal malabsorption, gastrointestinal complications, diabetes insipidus, reactive hypoglycemia, and others [3]. PCSK1cleaves its substrates at paired-basic amino acid residues [4]. More than 25 different targets of PCSK1 have been reported and most of them play an important role in metabolism [2, 3, 5]. Availability of several PCSK1 mouse models allowed investigating its role, expression, and tissue-specific substrates [5]. Until now, the role of PCSK1 has been studied primarily in brain, brainstem, pancreas, intestine, stomach, and more recently in immune cells [2, 5, 6].

Despite the evident influence of PCSK1 on adipose tissue and the known functions of other PCSKs in lipid metabolism, the role of PCSK1 specifically in lipid and cholesterol metabolism remains mostly unexplored [7]. Only a few association studies have reported a possible effect of PCSK1 on cholesterol. Two human PCSK1 mutations were linked with abnormal cholesterol levels in lipoprotein particles [8]. Lipoprotein particles are key vesicles in blood for transporting lipids and cholesterol to adipose tissue for storage and to other organs for utilization. One of those mutations was also associated with coronary artery disease in patients with type 2 diabetes.

*Correspondence:  seungbumc@gmail.com
1 The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA
2 Cerebrovascular Haematology-Immunology Priority Research Center, Medical Science Research Institute, Dongguk University Ilsan Hospital, Goyang 10326, Republic of Korea

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
In addition, the \textit{Pcsk1} gene is located in the region that was previously identified as a quantitative trait locus influencing high-density lipoprotein cholesterol (HDL-C) in a mouse linkage analysis [10]. In this study, we evaluated the effect of loss-of-function in PCSK1 on HDL-C and factors influencing HDL metabolism such as apolipoprotein A1 (APOA1), lecithin-cholesterol acyltransferase (LCAT), and phospholipid transfer protein (PLTP) [11].

**Results**

**Increased total serum APOA1 but similar HDL-C concentration in PCSK1\textsuperscript{N222D} mice**

To test whether the amino acid substitution (N222D) in PCSK1 influences HDL metabolism, serum HDL-C concentrations and the total APOA1 level were compared between PCSK1\textsuperscript{WT} and PCSK1\textsuperscript{N222D} males (8-week-old, fed standard chow diet). Serum APOA1 is the major apolipoprotein in HDL. It plays an important role in HDL-C metabolism and is used to estimate the number of HDL particles. Although serum HDL-C concentrations were similar (WT: 72.22±1.50 mg/dL vs. N222D: 72.32±1.70 mg/dL; \(P=0.84; n=13/\text{genotype}\)) (Fig. 1a), the serum total APOA1 levels (HDL-bound plus lipid-free forms) were increased in PCSK1\textsuperscript{N222D} (WT: 1.00±0.03 A.U. vs. N222D: 1.14±0.04 A.U.; \(P=0.05; n=5–6/\text{genotype}\)) (Fig. 2a). Concentrations of serum total cholesterol, LDL-C, and triglycerides were also measured in PCSK1\textsuperscript{N222D} mice (Figs. 1 B-D). The concentrations of total cholesterol (WT: 93.5±2.8 mg/dL vs. N222D: 90.5±2.4; \(P=0.47; n=8 \text{ or } 11/\text{genotype, Fig. 2b}\)) and triglyceride (WT: 101.6±4.5 mg/dL vs. N222D: 110.1±3.7 mg/dL; \(P=0.17; n=13/\text{genotype, Fig. 2d}\)) were similar between PCSK1\textsuperscript{WT} and PCSK1\textsuperscript{N222D}. LDL-C concentration was 11.6% decreased in PCSK1\textsuperscript{N222D} (WT: 19.9±0.9 mg/dL vs. N222D: 17.6±0.5 mg/dL; \(P=0.02; n=8 \text{ or } 11/\text{genotype, Fig. 2c}\)).

**Increased mature lipid-free APOA1 in PCSK1\textsuperscript{N222D} mice**

APOA1 is synthesized primarily in the liver and is secreted into circulation as a precursor. The immature proprotein is cleaved into its mature form in blood, where it is present either as mature lipid-free or HDL-bound protein [12, 13]. In order to determine if lipid-free or HDL-bound APOA1 was increased in total serum, the APOA1 level was evaluated in non-HDL depleted serum (NHDS) fraction, which contains only HDL-bound APOA1. The levels of APOA1 in NHDS fraction were similar between PCSK1\textsuperscript{WT} and PCSK1\textsuperscript{N222D} (WT: 1.00±0.04 A.U. vs. N222D: 0.88±0.04 A.U.; \(P=0.10; n=4–5/\text{genotype, Fig. 2b}\)). The maturation of APOA1 in PCSK1\textsuperscript{N222D} males was evaluated using an iso-electric focusing (IEF) assay. The ratio of mature/immature APOA1 was increased by approximately 33% in PCSK1\textsuperscript{N222D} (WT: 1.00±0.05 A.U. vs. N222D: 1.33±0.12 A.U.; \(P<0.03; n=5–6/\text{genotype, Fig. 2c}\)). These results suggest an increase in the lipid-free mature APOA1 in circulation. Since APOA1 is produced primarily in liver, \textit{Apoa1} mRNA and APOA1 protein levels were measured, and both mRNA and protein levels were not significantly different between PCSK1\textsuperscript{WT} and PCSK1\textsuperscript{N222D} (Fig. 3a, b).

**Moderately increased serum LCAT activity in PCSK1\textsuperscript{N222D} mice**

In circulation, the mature form of lipid-free APOA1 acquires phospholipid and cholesterol. This process is called APOA1 lipidation and initially results in the formation of nascent HDL particle (also known as pre-β HDL) (Fig. 4). The APOA1 in pre-β HDL activates LCAT, which subsequently converts free cholesterol into cholesteryl ester, thereby transforming pre-β HDL into larger spheroidal particles (α-HDL) [12, 14, 15]. The lipidation can be impaired by abnormal LCAT activity.
Serum LCAT substrate cleavage activity was increased by approximately 8% in PCSK1\textsuperscript{N222D} mice (WT: 1.00 ± 0.02 A.U. vs. N222D: 1.08 ± 0.02 A.U.; P = 0.05; n = 5–6/genotype, Fig. 5a). Trend towards an increased cholesteryl esterification (the ratio of cholesteryl ester to free cholesterol) was also observed in the PCSK1\textsuperscript{N222D} relative to PCSK1\textsuperscript{WT} (WT: 2.58 ± 0.44 A.U. vs. N222D: 3.18 ± 0.62 A.U.; P = 0.08; n = 6/genotype, data not shown), and this was a similar trend as the LCAT substrate cleavage activity.

**Discussion**

Although several human PCSK1 mutations have been associated with obesity and two human single nucleotide variants (SNVs) were linked with abnormal lipids in lipoprotein particles, the effect of PCSK1 on lipid and cholesterol metabolism remained largely unclear.
This study presents the first evaluation of HDL metabolism in the PCSK1N222D mice [5, 18]. Our data shows that a loss-of-function mutation in PCSK1 leads to increased mature lipid-free APOA1 levels and LCAT activity without increasing HDL-C. We observed a different expression pattern of APOA1 protein in liver and serum: similar APOA1 protein level in the liver versus increased APOA1 protein level in the serum of the PCSK1N222D mice relative to PCSK1WT mice. Similar hepatic APOA1 (accompanied with similar Apoa1 mRNA level) suggests that hepatic production of APOA1 (the first stage of HDL biogenesis) is unaffected by the mutation. These results may be suggestive of (1) an effort to increase lipidation of HDL particles, or (2) the result of increased HDL delipidation/catabolism (the last stage of HDL biogenesis), but this needs to be supported by additional experiments.

Further research on several additional aspects of HDL metabolism would help elucidating a more precise cause for the observed phenotype in PCSK1N222D mice. Firstly, cholesterol loading into HDL depends on a proper function of several membrane proteins such as ATP-binding cassette subfamily member 1 transporters (ABCA1, a cell membrane transporter involved in cholesterol export from the cells), ATP-binding cassette subfamily G member 1 (ABCG1), and scavenger receptor class B member 1 (SRB1) [12, 19]. Whether the function of any of these proteins is impaired in PCSK1N222D mice still needs to be evaluated. Secondly, elevated lipid-free APOA1 levels in circulation can be a result of increased catabolism.
of HDL particles. Such delipidated APOA1 is cleared preferentially by kidney and excreted via urine [19, 20]. Increased catabolism of HDL particles without concurrent increase in clearance by kidney remains a possible explanation for increased serum APOA1 levels and should be evaluated experimentally. Furthermore, HDL metabolism is affected by the concentration of different HDL subpopulations and their compositions (e.g. levels of serum amyloid A in HDL) [12]. These aspects have not yet to be investigated in this mouse model. Lastly, the oxidation of a specific amino acid on APOA1 was recently reported as important modification for HDL dysfunction in plasma [12]. This modification also remains to be tested. Interestingly, infusion of recombinant APOA1 and LCAT is being considered and investigated as a potential therapeutic strategy [12].

Our data shows that at least under some conditions HDL-C can remain low despite increased lipid-free APOA1 and increased LCAT activity.

Understanding HDL metabolism was initially of high interest because HDL-C is inversely associated with cardiovascular disease [12]. Historically, HDL-C was considered anti-atherogenic because of its role in reverse cholesterol transport (a process that mediates cholesterol efflux from macrophages in atherosclerotic lesions). The research over the last decades demonstrated that HDL has also anti-platelet, anti-oxidative, anti-inflammatory, anti-apoptotic and vasodilatory functions. Interestingly, knockdown of Pcsk1 in macrophages was recently demonstrated to increase secretion of proinflammatory factors [21]. Future research investigating macrophage-related inflammatory phenotype the Pcsk1N222D mice would be of interest.

Unlike previously published human association studies, our data shows that loss-of-function mutation in PCSK1 does not affect HDL-C in mice (although it does lead to lower LDL-C). The observed difference might be related to the location of the SNVs and their effect on gene expression or the ultimate function of the protein. In the mouse model used in this study, the mutation is in the protein coding region (A > G in codon 222, catalytic domain), which leads to a loss of protein’s function. The two SNVs that were previously associated with cholesterol and triglycerides in human studies are rs3811951 (intron 2, A > G) and rs155971 (intron 6, C > T). Both of the SNVs are intronic and their effect on PCSK1 expression is yet to be investigated. Until recently, the research was focused primarily on non-synonymous SNVs in the protein-coding regions. Interestingly, many of the newly discovered disease-associated SNVs are located in the non-coding region (intergenic or intronic) [22]. Our understanding of their role is only beginning to unravel [23]. Some of the intronic variants have been shown to impact splicing by interfering with splice site recognition or affecting the binding of RNA-binding proteins [24].

Aside from human studies, Pcsk1 was also an HDL-C candidate gene in a mouse quantitative trait locus in a cross between BALB/c and B6.C-H25c (a congenic strain carrying the BALB/c Apo2 allele — chromosome 1) [10]. The causal single nucleotide polymorphism (SNP) is yet to be identified. Nonetheless, several Pcsk1
SNPs between BALB/cJ and B6 have been annotated in The Jackson Laboratory Mouse dbSNP data-base [25], including rs8274592 (a coding but synonymous SNP), rs8267200 (in the 3’ untranslated region (UTR) of messenger RNA), and various predicted intronic SNPs. The 3’-UTR can contain binding sites for regulatory proteins and microRNAs that control post-transcriptional expression of the gene or localization of the protein [26, 27]. Lastly, two different splice isoforms of Pcsk1 have been annotated in the Ensemble. The difference between these two isoforms remains unexplored and the SNVs and SNPs between BALB/cJ and B6 have a unique effect on each isoform.

Our study provided characterization of HDL metabolism in PCSK1N222D mouse model. Despite the increased lipid-free mature APOA1 and moderately increased LCAT activity, HDL-C levels remained unchanged in mice with a dysfunctional PCSK1 (caused by a SNP in the region coding for catalytic domain).

Conclusions
Overall, this study provides the first preclinical evidence for a novel and unexpected function of PCSK1 in cholesterol metabolism. We suggest further studies to reveal underlying molecular mechanisms by which PCSK1 modulates serum APOA1 concentration and LCAT function without affecting serum HDL cholesterol concentration.

Methods
Animals, housing, and diet
Animal studies were approved by The Jackson Laboratory’s Institutional Animal Care and Use Committee. All animals were housed at The Jackson Laboratory, which is approved by the American Association for Accreditation of Laboratory Animal Care and maintained in a pathogen-free and climate-controlled facility with a 12-h light/dark cycle and fed ad libitum (except for the times of blood collection as described below) a normal chow diet containing 6% fat (5K52 LabDiet®, PMI Nutrition International, St. Louis, MO, USA) [7]. The PCSK1 loss-of-function mutant mouse model (C57BL/6 J-Pcsk1<sup>N222D</sup>/J (JAX® #006,699), referred to as PCSK1<sup>N222D</sup> throughout the rest of the article) contains an adenine-to-guanine transition, which leads to an amino acid substitution in the catalytic domain from asparagine (N) to aspartate (D) at codon 222. Only 8-week-old males (20 ~ 25 g) were utilized in the present study.

Blood collection and serum preparation
Mice were fasted from 07:00 am to 11:00 am and then retro-orbitally bled; 100–150 µl of blood was collected in a 1.5 ml tube for serum. Serum was isolated by centrifugation at 15,000 rpm for 5 min at room temperature within 2 h of the bleed. Collected supernatant was stored at −20 °C until needed for experimental measurements. Interventions studies involving animals or humans, and other studies that require ethical approval, must list the authority that provided approval and the corresponding ethical approval code.

Analysis of HDL cholesterol, total cholesterol, and triglyceride
The HDL-C concentration was measured using an HDL-D reagent kit (Beckman Coulter Inc., Palo Alto, CA, USA) on a Beckman Synchron DXC (Beckman Coulter Inc., Palo Alto, CA, USA). The total cholesterol concentration was measured using a CHOL reagent kit (Beckman Coulter Inc., Palo Alto, CA, USA). Low-density lipoprotein cholesterol (LDL-C) concentration was estimated by subtracting HDL-C concentration from the total cholesterol. Triglycerides concentration was measured using a triglyceride reagent kit (Beckman Coulter Inc., Palo Alto, CA). The methods used for measuring HDL-C, total cholesterol, and triglycerides concentrations were validated in mice and were used in our previous publications [7]. Measurement for total cholesterol and LDL-C in certain serum samples were unsuccessful for technical reasons. These measurements were excluded from statistical analyses. Thus, while HDL-C comparison included a total of 13 samples per genotype, the number of animals per genotype in the comparison of total cholesterol and LDL-C is slightly lower.

Western blot (WB) for APOA1
APOA1 was measured in non-HDL depleted serum (NHDS) and liver. NHDS was collected as previously described [7]. Briefly, the NHDS was prepared by separating the sample into 2 parts: 1) a precipitated fraction with all of the non-HDL lipoprotein particles (namely, VLDL, LDL, and IDL) as well as lipid-free APOA1, and 2) supernatant containing HDL and HDL-bound APOA1 (the NHDS fraction). This precipitation was done by dextran sulfate and magnesium chloride precipitation method. Each sample was mixed with one-tenth volume of the chemical precipitation reagent containing dextran sulfate (10 g/L) and magnesium chloride (500 mM), which lead to precipitation of non-HDL particles [28]. To compare the APOA1 in NHDS by WB [7], the samples were diluted in T-PER agent (Roche, Indianapolis, IN, USA) and a protease inhibitors cocktail tablet was added (Roche, Indianapolis, IN, USA). Equal volumes (μl) of diluted NHDS samples were electrophoresed using sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a membrane, which was then probed using primary polyclonal rabbit APOA1 antibody (ab20453, 1/1,000,
iso-electro focusing (IEF) for mature and immature APOA1
Serum (50 μl) was combined with protein extraction reagent type IV containing 37.5 μl of 200 mM tributylphosphine solution (Sigma-Aldrich, St. Louis, MO) and 15 μl of 1 M acrylamide. The resulting mixture was incubated at room temperature for 1.5 h and centrifuged at 15,000 rpm for 10 min. Collected supernatant was mixed with 9 volumes of acetone, incubated for 1 h at room temperature, and centrifuged at 4,000 rpm for 30 min. The obtained precipitated proteins were dissolved in 200 μl of protein extraction reagent type IV and the total protein concentration was measured by Bradford assay.

The separation of mature and immature APOA1 was done using IEF method according to the manufacturer’s instructions. Briefly, serum proteins were separated using gel electrophoresis technique in two consecutive steps: 1) the 1st dimension separation by molecular weights using SDS-PAGE, and 2) the 2nd dimension separation by isoelectric points using IEF gel: equal amount of total protein (15 μg) in IEF pH 3–7 sample buffer was loaded and run on Novex® pH 3–10 IEF gel (Invitrogen, Grand Island, NY, USA) at 100 V, 200 V, and 500 V for 1 h at each voltage. Then, the two forms of APOA1 were visualized by WB using APOA1 antibody as described above, and their band intensities were measured using ImageJ. Relative levels were calculated by dividing the protein band intensities of mature APOA1 by immature APOA1.

Lecithin-cholesterol acyltransferase (LCAT) activity
LCAT substrate reagent (1 μl) was added to a mixture of 5 μl of serum and 195 μl LCAT assay buffer (150 mM NaCl, 10 mM Tris, 1 mM EDTA, 4 mM 2-mercaptoethanol, pH 7.4). The mixture (LCAT substrate reagent mixed with serum in LCAT assay buffer) was incubated for 30 min at 37 °C. Then, the reaction was stopped by adding the reconstituted READ reagent buffer (READ reagent, 150 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.4). The mixture was transferred to a black 96-well microtiter plate and analyzed at excitation wavelength of 340 nm and emission wavelengths of 390 nm (hydrolyzed substrate) and 470 nm (non-hydrolyzed substrate) according to the manufacturer’s instructions (LCAT activity assay kit, Roar Biomedical, Inc., Calverton, NY, USA). The LCAT activity was determined by the ratio of the two emission intensities (390/470 nm).

Cholesterol and cholesteryl esters quantitation
Quantitation of cholesterol and cholesteryl esters was done using colorimetric Cholesterol/Cholesteryl Ester Quantitation kit (EMD Millipore, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, serum was diluted 20-fold in cholesterol assay buffer and mixed with cholesterol probe, enzyme mix, and cholesterol esterase to quantify total cholesterol (cholesterol and cholesteryl esters). Quantification of cholesterol alone was done the same, except the cholesteryl esterase was omitted in the reaction. The intensity of the color (representing the level of total cholesterol and cholesterol) was measured by exposing samples to 575 nm wavelength. Concentration was calculated using colorimetric standard.

Phospholipid transfer protein (PLTP) activity and protein level
PLTP activity was measured using a colorimetric PLTP activity assay kit (Roar Biomedical, Inc., Calverton, NY, USA) according to the manufacturer’s instructions. Briefly, the activity was measured by combining serum (3 μl) with a mixture of 3 μl donor particles in 44 μl 1X assay buffer (150 mM NaCl, 10 mM Tris, 2 mM EDTA, pH 7.4). The samples were transferred to a black 96-well microtiter plate and 50 μl acceptor particles were added to each sample. The samples were incubated for 20 min at 37 °C, and then read at excitation wavelength of 465 nm and emission wavelength of 535 nm. To determine PLTP protein level, equal volume (μl) of serum was electrophoresed and probed using primary polyclonal rabbit PLTP antibody (ab20453, Abcam, Cambridge, MA, USA) and secondary antibody for anti-rabbit IgG (7074S, 1/5,000, HRP-linked secondary, Cell Signaling Technology Inc., Danvers, MA, USA). The APOA1 band intensity was normalized by β-actin protein band intensity. For both serum and liver, protein band intensities were measured using ImageJ (National Institute of Health, Bethesda, MD, USA).

Abcam, Cambridge, MA, USA) and secondary antibody for anti-rabbit IgG (7074S, 1/5,000, HRP-linked secondary, Cell Signaling Technology Inc., Danvers, MA, USA). The APOA1 band intensity was normalized using total protein concentration (μg/μl), which was determined by a Bradford assay (Sigma Life Sciences, St. Louis, MO, USA).

To evaluate APOA1 in liver, the tissues were ground frozen on dry ice and diluted in T-PER agent (Roche, Indianapolis, IN, USA). Then, a protease inhibitors cocktail tablet was added (Roche, Indianapolis, IN, USA). Total protein concentration (μg/μl), which was determined using a Bradford assay (Sigma Life Sciences, St. Louis, MO, USA). Equal amount of protein (μg) was electrophoresed using SDS-PAGE and probed using primary polyclonal rabbit APOA1 antibody (ab20453, Abcam, Cambridge, MA, USA; 1/1,000) and primary polyclonal rabbit β-actin antibody as control (ab8227, 1/25,000, Abcam, Cambridge, MA, USA). The APOA1 band intensity was normalized by β-actin protein band intensity. For both serum and liver, protein band intensities were measured using ImageJ (National Institute of Health, Bethesda, MD, USA).

Lecithin-cholesterol acyltransferase (LCAT) activity
LCAT substrate reagent (1 μl) was added to a mixture of 5 μl of serum and 195 μl LCAT assay buffer (150 mM NaCl, 10 mM Tris, 1 mM EDTA, 4 mM 2-mercaptoethanol, pH 7.4). The mixture (LCAT substrate reagent mixed with serum in LCAT assay buffer) was incubated for 30 min at 37 °C. Then, the reaction was stopped by adding the reconstituted READ reagent buffer (READ reagent, 150 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.4). The mixture was transferred to a black 96-well microtiter plate and analyzed at excitation wavelength of 340 nm and emission wavelengths of 390 nm (hydrolyzed substrate) and 470 nm (non-hydrolyzed substrate) according to the manufacturer’s instructions (LCAT activity assay kit, Roar Biomedical, Inc., Calverton, NY, USA). The LCAT activity was determined by the ratio of the two emission intensities (390/470 nm).

Phospholipid transfer protein (PLTP) activity and protein level
PLTP activity was measured using a colorimetric PLTP activity assay kit (Roar Biomedical, Inc., Calverton, NY, USA) according to the manufacturer’s instructions. Briefly, the activity was measured by combining serum (3 μl) with a mixture of 3 μl donor particles in 44 μl 1X assay buffer (150 mM NaCl, 10 mM Tris, 2 mM EDTA, pH 7.4). The samples were transferred to a black 96-well microtiter plate and 50 μl acceptor particles were added to each sample. The samples were incubated for 20 min at 37 °C, and then read at excitation wavelength of 465 nm and emission wavelength of 535 nm. To determine PLTP protein level, equal volume (μl) of serum was electrophoresed and probed using primary polyclonal rabbit PLTP antibody (ab20453, 1/1,000, Abcam, Cambridge, MA, USA) and secondary antibody for anti-rabbit IgG (7074S, 1/5,000, HRP-linked secondary, Cell Signaling Technology Inc., Danvers, MA, USA). The APOA1 band intensity was normalized by β-actin protein band intensity. For both serum and liver, protein band intensities were measured using ImageJ (National Institute of Health, Bethesda, MD, USA).

Lecithin-cholesterol acyltransferase (LCAT) activity
LCAT substrate reagent (1 μl) was added to a mixture of 5 μl of serum and 195 μl LCAT assay buffer (150 mM NaCl, 10 mM Tris, 1 mM EDTA, 4 mM 2-mercaptoethanol, pH 7.4). The mixture (LCAT substrate reagent mixed with serum in LCAT assay buffer) was incubated for 30 min at 37 °C. Then, the reaction was stopped by adding the reconstituted READ reagent buffer (READ reagent, 150 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.4). The mixture was transferred to a black 96-well microtiter plate and analyzed at excitation wavelength of 340 nm and emission wavelengths of 390 nm (hydrolyzed substrate) and 470 nm (non-hydrolyzed substrate) according to the manufacturer’s instructions (LCAT activity assay kit, Roar Biomedical, Inc., Calverton, NY, USA). The LCAT activity was determined by the ratio of the two emission intensities (390/470 nm).

Cholesterol and cholesteryl esters quantitation
Quantitation of cholesterol and cholesteryl esters was done using colorimetric Cholesterol/Cholesteryl Ester Quantitation kit (EMD Millipore, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, serum was diluted 20-fold in cholesterol assay buffer and mixed with cholesterol probe, enzyme mix, and cholesterol esterase to quantify total cholesterol (cholesterol and cholesteryl esters). Quantification of cholesterol alone was done the same, except the cholesteryl esterase was omitted in the reaction. The intensity of the color (representing the level of total cholesterol and cholesterol) was measured by exposing samples to 575 nm wavelength. Concentration was calculated using colorimetric standard.

Phospholipid transfer protein (PLTP) activity and protein level
PLTP activity was measured using a colorimetric PLTP activity assay kit (Roar Biomedical, Inc., Calverton, NY, USA) according to the manufacturer’s instructions. Briefly, the activity was measured by combining serum (3 μl) with a mixture of 3 μl donor particles in 44 μl 1X assay buffer (150 mM NaCl, 10 mM Tris, 2 mM EDTA, pH 7.4). The samples were transferred to a black 96-well microtiter plate and 50 μl acceptor particles were added to each sample. The samples were incubated for 20 min at 37 °C, and then read at excitation wavelength of 465 nm and emission wavelength of 535 nm. To determine PLTP protein level, equal volume (μl) of serum was electrophoresed and probed using primary polyclonal rabbit PLTP antibody (ab20453, 1/1,000, Abcam, Cambridge, MA, USA) and secondary antibody for anti-rabbit IgG (7074S, 1/5,000, HRP-linked secondary, Cell Signaling Technology Inc., Danvers, MA, USA). The APOA1 band intensity was normalized by β-actin protein band intensity. For both serum and liver, protein band intensities were measured using ImageJ (National Institute of Health, Bethesda, MD, USA).
HPR-linked anti-rabbit IgG antibody (7074S, 1/5,000, Cell Signaling Technology, Inc., Danvers, MA, USA).

Quantitative polymerase chain reaction (qPCR) for Apoa1

Livers were collected from 8-week-old male mice. Prior to the tissue collection, males were housed individually for 4 days, fasted for 4 h (7 am to 11 am) on the day of tissue collection, sacrificed by cervical dislocation, and perfused using PBS. Total RNA from whole liver was extracted using a Trizol Plus RNA Purification kit (Invitrogen Life Technologies, Grand Island, NY, USA). Complementary DNA (cDNA) was synthesized using an Omniscript Reverse Transcription kit (Qiagen, Valencia, CA) and used for qPCR with SYBR green (Applied Biosystems, Inc., Foster City, CA, USA) and Apoa1 primers (Forward: 5′ CACATATAGACGCCAGAGGGAAGGTTTT 3′ and Reverse: 5′ CTGAGGGGTGTGGTGAC 3′ from Primerdesign Ltd., Southampton, UK). The Apoa1 expression level was normalized with β-actin (Forward: 5′ GCTTCTTTT-GCACGTCTTCTCG 3′ and Reverse: 5′ CCCACGATGGAGGGGAATAC 3′ from Primerdesign Ltd., Southampton, UK). The relative expression difference was calculated using LinRegPCR (v11.0) [29] and Relative Expression Software Tool (REST®) [30].

Statistics

All data represent the mean ± standard error of the mean (SEM) from the number of animals of each group, unless specified otherwise. Comparing means of more than two groups was performed using one-way ANOVA, followed by Tukey’s post-hoc test for multiple comparisons between specific groups. For comparisons of 2 groups, the non-parametric Mann–Whitney test was used to calculate levels of significance. Calculations of significance were done using Prism 8 (GraphPad Software, San Diego, CA). Level of statistical significance: *P < 0.05, **P < 0.01.

Abbreviations

PCS1: Proprotein convertase subtilisin/kexin type 1; HDL: High-density lipoprotein; HDL-C: High-density lipoprotein cholesterol; APO1: Apolipoprotein A1; LCAT: Lecithin-cholesterol acyltransferase; PLTP: Phospholipid transfer protein; VLDL: Very low-density lipoprotein; LDL: Low-density lipoprotein;IDL: Intermediate-density lipoprotein; RT: Room temperature; WB: Western blot; SDS-PAGE: Sodium dodecyl sulphate–polyacrylamide gel electrophoresis; IEF: Iso-electro focusing; qPCR: Quantitative polymerase chain reaction; QTL: Quantitative trait loci; SEM: Standard error of the mean; ANOVA: Analysis of variance; SNP: Single nucleotide variant; SNV: Single nucleotide polymorphism; ABCA1: ATP-binding cassette subfamily member 1 transporter; ABCG1: ATP-binding cassette subfamily G member 1; SRB1: Scavenger receptor class B member 1.

Acknowledgements

In memory of Beverly Paigen (1938-2020). We thank Joanne Curer for editorial advice, Kyle Beauchemin, George Sutphin, Christopher McCarty, and Elisabeth Adkins for scientific discussion and feedback; Beverly Macy and Rachel Gott for animal care and serum collection; Sue Grindle for HDL cholesterol measurement; Susan Sheehan and Kenneth Walsh for general technical support.

Authors’ contributions

Conceptualization, S.C and R.K.; methodology, A.K. and S.C.; formal analysis, A.K., N.K.; investigation, A.K. and S.C.; writing—original draft preparation, S.C. and R.K.; writing—review and editing, A.K, N.K., R.K. and S.C.; supervision, R.K. and S.C.; project administration, R.K. and S.C.; funding acquisition, R.K. and S.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by HL081162, HL077796 and HL095668 from the National Heart, Lung and Blood Institute to Drs. Ron Korstanje and Beverly J. Paigen, and by the National Research Foundation (NRF); Basic Science Research Program (NRF- 2016R1A6A3A1193516 and NRF-2019R1C1C1002909) to Dr. Seungbum Choi, funded by the Korean government.

Availability of data and materials

All data generated or analyzed during the current study were included in this published article.

Declarations

Competing interests

The authors declare that there is no financial conflict of interests to publish these results.

Received: 27 October 2021   Accepted: 29 December 2021

Published online: 07 January 2022

References

1. Seidah NG, Sadr MS, Cretien M, Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and cooperative functions. J Biol Chem. 2013;288(30):21473–91.
2. Ramos-Molina B, Martin MG, Lindberg J. PCSK1 variants and human obesity. Prog Mol Biol Transl Sci. 2016;140:40–74.
3. Stijnen T, Ramos-Molina B, O’Rahilly S, Creemers JW. PCSK1 mutations and human endothropathies: from obesity to gastrointestinal disorders. Endocr Rev. 2016;37(4):347–71.
4. Seidah NG, Mayer G, Zaid A, Rousselle E, Nassoury N, Poinier S, et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol. 2008;40(6–7):1111–25.
5. Shalaya M, Lindberg J. Mouse models of human proprotein convertase insufficiency. Endocr Rev. 2021;42(3):259–94.
6. Refaei S, Gagnon S, Gagnon H, Desjardins R, D’Anjou F, D’Oreilles-Juste P, et al. Disruption of proprotein convertase 1/3 (PC1/3) expression in mice causes innate immune defects and uncontrolled cytokine secretion. J Biol Chem. 2012;287(18):14703–17.
7. Choi S, Aljakna A, Srivastava U, Peterson BR, Deng B, Prat A, et al. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Dis. 2013;12:112.
8. Kulanuwat S, Santiprabhob J, Phonrat B, Limwongse C, Tungtrongchitr A, Chongviriyaphan N, et al. Association between rs155971 in the PCSK1 gene and the lipid profile of obese Thai children: a family-based study. Genet Mol Res. 2015;14(3):9136–44.
9. Wei X, Ma X, Lu R, Bai G, Zhang J, Deng R, et al. Genetic variants in PCSK1 gene are associated with the risk of coronary artery disease in type 2 diabetes in a Chinese Han population: a case control study. PLoS One. 2014;9(11):e87168.
10. Welch CL, Bretchcher S, Wen PZ, Mehrabian M, Latib N, Fruchart-Najib J, et al. Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain. Physiol Genomics. 2004;17(1):48–59.
11. Kujiraoka T, Nanjee MN, Oku T, To M, Nagano M, Cooke CJ, et al. Effects of intravenous apolipoprotein A-I/Phosphatidycholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol. 2003;23(9):1653–63.
12. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13(6):445–64.
13. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry. 2007;46(28):8445–50.
14. Chen X, Burton C, Song X, McNamara L, Langella A, Cianetti S, et al. An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration. Int J Biol Sci. 2009;5(5):489–99.
15. Forte TM, Bielicki JK, Geth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res. 1995;36(1):148–57.
16. Albers JJ, Pitman W, Wolfbauer G, Cheung MC, Kennedy H, Tu AY, et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J Lipid Res. 1999;40(2):295–301.
17. Huuskonen J, Ollkonen VM, Ehnholm C, Metso J, Julkunen I, Jauhiainen M. Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion. Biochemistry. 2000;39(51):16092–8.
18. Lloyd DJ, Bohan S, Gekakis N. Obesity, hyperphagia and increased metabolic efficiency in P1 mutant mice. Hum Mol Genet. 2006;15(11):1884–93.
19. Jomard A, Osto E. High density lipoproteins: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020;7:39.
20. Braschi S, Neville TA, Maugeas C, Ramsamy TA, Seymour R, Sparks DL. Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry. 2000;39(18):5441–9.
21. Duhamel M, Rodet F, Murgoci AN, Desjardins R, Gagnon H, Wisztorz M, et al. The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways. Sci Rep. 2016;6:19360.
22. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–77.
23. Li MJ, Yan B, Sham PC, Wang J. Exploring the function of genetic variants in the non-coding genomic regions: approaches for identifying human regulatory variants affecting gene expression. Brief Bioinform. 2015;16(3):393–412.
24. Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17(1):19–32.
25. Bult CJ, Blake JA, Smith CL, Kadiri JA, Richardson JE, Mouse Genome Database G. Mouse genome database (MGD) 2019. Nucleic Acids Res. 2019;47(D1):D801–6.
26. Erson-Bensan AE. RNA-biology ruling cancer progression? Focus on 3’UTRs and splicing. Cancer Metastasis Rev. 2020;39(3):887–901.
27. Pereira-Castro I, Moreira A. On the function and relevance of alternative 3’-UTRs in gene expression regulation. Wiley Interdiscip Rev RNA. 2021;12(3):1653.
28. Warnick GR, Benderzon J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28(6):1379–88.
29. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339(1):62–6.
30. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.